Log in to search using one of your social media accounts:

 

More Chemo May Not Equal Better Outcomes in Ovarian Ca (CME/CE)
(MedPage Today) -- Recurrence, survival acceptable with 3 cycles in clear cell carcinoma (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 17, 2017 Category: Hematology Source Type: news

More Chemo May Not Equal Better Outcomes in Ovarian Ca (CME/CE)
(MedPage Today) -- Recurrence, survival acceptable with 3 cycles in clear cell carcinoma (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 16, 2017 Category: Primary Care Source Type: news

Researchers pinpoint two genes that trigger severest form of ovarian cancer
Researchers create first mouse model of ovarian clear cell carcinoma using data from human cancer genome atlas. They show how when the genes ARID1A and PIK2CA are mutated in specific ways, the result is ovarian cancer 100 percent of the time. They show that a known drug can suppress tumor growth. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 27, 2015 Category: Science Source Type: news

Researchers pinpoint 2 genes that trigger severest form of ovarian cancer
(University of North Carolina Health Care) Researchers from the UNC School of Medicine create the first ever mouse model of ovarian clear cell carcinoma using data gleaned from the human cancer genome atlas. They show how when the genes ARID1A and PIK2CA are mutated in specific ways, the result is the most severe form of ovarian cancer 100 percent of the time. In their paper in Nature Communications, they also show that a known drug can suppress tumor growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 27, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson's David M. Gershenson, MD, Receives IGCS's Award for Excellence in Gynecologic Oncology
For his myriad clinical, organizational and scientific accomplishments in the field of gynecologic oncology and the health and well-being of women, David M. Gershenson, M.D. has been recognized with the International Gynecology Cancer Society's (IGCS) Award of Excellence. Gershenson, professor and past chair of the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, received the award at the IGCS's 15th Biennial Meeting in Melbourne, Australia. William J. Hoskins, MD., of Memorial Sloan Kettering, also was honored with the distinction.The IGCS is a not-for-prof...
Source: M. D. Anderson Cancer Center - News Releases - November 10, 2014 Category: Cancer & Oncology Source Type: news

ZymoGenetics Initiates Phase II Renal Cell Cancer Trial
ZymoGenetics has initiated Phase II testing of Interleukin 21 in combination with Nexavar tablets, in patients with advanced renal cell cancer. The primary objective of the open label multi-center Phase II study is to characterize safety of Interleukin 21 (IL-21) with Nexavar at the recommended dose; a secondary objective is to evaluate anti-tumor activity, which will be assessed by evaluating tumor response and progression free survival. The trial is expected to enroll approximately 30 patients. The study is evaluating the combination in patients with clear cell carcinoma, which accounts for 85% of all renal cell tumors. ...
Source: Kidney Cancer Association - January 16, 2008 Category: Urology & Nephrology Source Type: news